2438 related articles for article (PubMed ID: 8060899)
1. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences.
Vile RG; Hart IR
Ann Oncol; 1994; 5 Suppl 4():59-65. PubMed ID: 8060899
[TBL] [Abstract][Full Text] [Related]
2. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.
Vile RG; Hart IR
Cancer Res; 1993 Sep; 53(17):3860-4. PubMed ID: 8395331
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo targeting of gene expression to melanoma cells.
Vile RG; Hart IR
Cancer Res; 1993 Mar; 53(5):962-7. PubMed ID: 8439971
[TBL] [Abstract][Full Text] [Related]
4. The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma.
Hollingsworth SJ; Darling D; Gäken J; Hirst W; Patel P; Kuiper M; Towner P; Humphreys S; Farzaneh F; Mufti GJ
Br J Cancer; 1996 Jul; 74(1):6-15. PubMed ID: 8679459
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.
Vile R; Miller N; Chernajovsky Y; Hart I
Gene Ther; 1994 Sep; 1(5):307-16. PubMed ID: 7584096
[TBL] [Abstract][Full Text] [Related]
6. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
Parker SE; Khatibi S; Margalith M; Anderson D; Yankauckas M; Gromkowski SH; Latimer T; Lew D; Marquet M; Manthorpe M; Hobart P; Hersh E; Stopeck AT; Norman J
Cancer Gene Ther; 1996; 3(3):175-85. PubMed ID: 8725882
[TBL] [Abstract][Full Text] [Related]
7. Effects of modulators of tyrosinase activity on expression of murine interleukin-2 cDNA driven by the tyrosinase promoter.
Miller N; Vile RG; Hart IR
Melanoma Res; 1995 Apr; 5(2):75-81. PubMed ID: 7620342
[TBL] [Abstract][Full Text] [Related]
8. Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma.
Walsh P; Dorner A; Duke RC; Su LJ; Glode LM
J Natl Cancer Inst; 1995 Jun; 87(11):809-16. PubMed ID: 7791230
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model.
Bonnekoh B; Greenhalgh DA; Chen SH; Block A; Rich SS; Krieg T; Woo SL; Roop DR
J Invest Dermatol; 1998 Jun; 110(6):867-71. PubMed ID: 9620291
[TBL] [Abstract][Full Text] [Related]
10. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
Doucet C; Meazza R; Pottin-Clemenceau C; Scudeletti M; Brouty-Boye D; Ferrini S; Alileche A; Taoufik Y; Jasmin C; Azzarone B; Indiveri F
Melanoma Res; 1997 Aug; 7 Suppl 2():S7-17. PubMed ID: 9578412
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
12. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene.
Cao G; Zhang X; He X; Chen Q; Qi Z
In Vivo; 1999; 13(2):181-7. PubMed ID: 10363176
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
14. Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines.
Guillaume T; Sekhavat M; Rubinstein DB; Hamdan O; Symann ML
Cancer Res; 1993 Jul; 53(13):3139-44. PubMed ID: 8319222
[TBL] [Abstract][Full Text] [Related]
15. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
Emiliusen L; Gough M; Bateman A; Ahmed A; Voellmy R; Chester J; Diaz RM; Harrington K; Vile R
Gene Ther; 2001 Jul; 8(13):987-98. PubMed ID: 11438833
[TBL] [Abstract][Full Text] [Related]
16. Immunobiologic effects of cytokine gene transfer of the B16-BL6 melanoma.
Strome SE; Krauss JC; Cameron MJ; Forslund K; Shu S; Chang AE
Arch Otolaryngol Head Neck Surg; 1993 Dec; 119(12):1289-95. PubMed ID: 17431982
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma.
Okada Y; Okada N; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T
Cancer Gene Ther; 2005 Jul; 12(7):608-16. PubMed ID: 15746944
[TBL] [Abstract][Full Text] [Related]
18. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity.
Heller L; Pottinger C; Jaroszeski MJ; Gilbert R; Heller R
Melanoma Res; 2000 Dec; 10(6):577-83. PubMed ID: 11198480
[TBL] [Abstract][Full Text] [Related]
19. Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model.
Tanaka K; Towata S; Nakao K; Mizuguchi H; Hayakawa T; Niwa M; Ishii N; Nagayama Y
Clin Endocrinol (Oxf); 2003 Dec; 59(6):734-42. PubMed ID: 14974915
[TBL] [Abstract][Full Text] [Related]
20. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
Stoppacciaro A; Forni G; Colombo MP
Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
